Lurtotecan(OSI-211) CAS:149882-10-0, a potent topoisomerase I inhibitor, belongs to the camptothecin family of anticancer agents. Featuring a planar pentacyclic ring system, this molecule displays enhanced aqueous solubility and stability. Lurtotecan’s unique E-ring lactone structure enables it to form a covalent complex with DNA, leading to the inhibition of DNA replication and ultimately inducing cell death.
Introduction to the Application: In pharmaceutical research and development, Lurtotecan has emerged as a promising candidate for the treatment of various solid tumors. Its distinct mode of action and improved pharmacokinetic profile have prompted extensive preclinical and clinical investigations, including phase II trials. Lurtotecan shows potential in overcoming drug resistance and improving therapeutic outcomes in patients with refractory cancers, such as ovarian, colorectal, and small-cell lung carcinomas.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
